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Background: To assess role of 
immunohistochemistry in identifying primary and 
secondary ovarian malignancies. 
Methods: In this descriptive cross sectional study 
65 cases of ovarian malignancies diagnosed during 
the year 2001, with a limited immunohistochemistry 
support were included. An equal number of cases (65 
cases) diagnosed during the year 2012, with an 
extended immunochemistry support,  were used for 
the comparison. Immunostains used in these cases 
were CK, CK7, CK20, Cdx2, PLAP, WT1, inhibin, 
Calretenin, Melan A, CD99, GCDFP15, 
Mammoglobin LCA, CEA, AFP, CD30 and CD10. 
Results: The frequency of metastatic carcinoma has 
changed tremendously being 3% in 2001 and 35.4% 
in 2012. The frequencies of other malignancies in 
2001 in descending order of frequency were surface 
epithelial tumour (74.2%), germ cell tumours (16.2%), 
sex cord stromal tumours (1.5%) and others (3%). In 
2012, apart from metastatic carcinoma, the frequency 
in descending order of frequency was surface 
epithelial tumours (35.4%), germ cell tumours 
(18.5%), sex cord stromal tumours (16.2%), and others 
(4.6%). There was not much difference in median 
ages (42.74 +15.4 and 39.54 + 15.8) 
Conclusion: IHC has helped in identifying 
primary and secondary ovarian  malignancies. 
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Introduction 
   Ovarian cancer is one of the most lethal and common 
malignancies of females. About 21,880 women were 
diagnosed and 13,850 women died of ovarian cancer 
in 2010. 1 A total of 45,000 women were diagnosed 
with ovarian cancer in 2008 in Europe. 2  Although 
there are no known definite causes of ovarian 
malignancy, there are some risk factors. 3  Nulliparity, 
obesity, women taking hormone replacement therapy 
for more than five years increase the risk of ovarian 
cancers. 4  Moreover women harbouring BRCA1 and 
BRCA2 mutations are at increased risk. 5 Pathogenesis  
 
of ovarian carcinoma has been subject of interest in the 
recent years. Different pathogenesis of ovarian 
malignancies has important implications regarding the 
prognosis. 6  It is very important to accurately classify 
and diagnose ovarian tumours due to different 
treatment options. Usually tumours with typical 
morphological features do not pose any diagnostic 
difficulty, but not uncommonly they share similar 
patterns. Pattern recognition is very important. At 
times, morphology alone is not sufficient and one has 
to rely on ancillary studies. Immunohistochemistry 
(IHC) over the years has developed as a very helpful 
diagnostic adjunct. It helps to classify tumours into 
surface epithelial, germ cell, sex cord stromal tumours 
and metastatic tumours. It has played a very 
important role in differentiating primary ovarian 
malignancies from tumours metastatic to ovary. The 
role of IHC has very important treatment and 
prognostic implications.7 No single immunostain is 
diagnostic. Usually a panel of immunostains has to be 
applied to reach a final diagnosis. IHC has played a 
vital role in differentiating between primary ovarian 
carcinomas from metastasis from colon, breast, 
pancreas, appendix etc. 6, 7  The rationale of this study 
was to highlight the value of IHC in identifying 
primary and secondary ovarian malignancies. 
Patients and Methods  
 This was a descriptive cross sectional study 
carried out in department of Pathology, Shaukat 
Khanum Memorial Cancer Hospital and Research 
centre. The department receives specimens from all 
over the country and shares a major burden of cancer 
diagnosis.. A total of 65 cases of ovarian malignancies 
diagnosed during the year 2001 were randomly 
selected. This was the time when 
immunohistochemistry used to be applied on a very 
limited scale. In 2001 immunostains which used to be 
applied were Cytokeratin (CK), Leucocyte common 
antigen (LCA), Inhibin, CK7 and Placental Alkaline 
Phosphatase (PLAP). Mean, median and mode were 
calculated for quantitative variable like patient’s age 
and frequencies and percentages were calculated for 
tumour type. An equal number of cases (65 cases) 
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diagnosed during the year 2012 were used for the 
comparison and same variables were calculated. Now 
we use extended panel of immunohistochemistry for 
cancer diagnosis. Immunostains used in these cases 
were CK, CK7, CK20, Wilms tumour 1 (WT1), Caudal 
type homeo box transcription factor 2 (Cdx2), PLAP, 
inhibin, Calretenin, MelanA, Cluster of differentiation 
99 (CD99), Gross cystic disease fluid protein 15 
(GCDFP15), LCA, Carcinoma embryonic antigen 
(CEA), Alpha fetoprotein (AFP), and Cluster of 
differentiation 10 (CD10) and Cluster of differentiation 
30 (CD 30). Results obtained for the year 2001 and 
2012 were compared to see if immunohistochemistry 
has played any role in identifying primary and 
secondary malignancies of ovary. 
Results 
     Median ages of patients, diagnosed with ovarian 
malignancies, during the years 2001 and 2012, were in 
approximation, i.e.,  42.74 +15.4 during 2001 and 39.54 
+15.8 during 2012. In 2001, out of 49 cases of surface 
epithelial tumours, 81.6% cases presented in 4th to 6th 
decades. A total of 10 out of 12 cases (83.3%) of germ 
cell tumours presented in 2nd decade. One case of 
metastatic carcinoma presented in 4th and one in 5th 
decade. In 2012, 17 out of 23 (74%) surface epithelial 
tumours presented in 4th to 6th decade, 9 out of 12 
cases (75%) of germ cell tumours in 2nd to 3rd decade 
and 9 out of 23 cases of metastatic carcinoma (39%) in 
4th decade and five cases (21%) each in 5th and 6th 
decade. In 2001 metastatic tumours were 3%, but in 
2012 frequency of metastatic tumours escalated to 
35.4%. Surface epithelial tumours constituted 74.2% in 
2001, but in 2012 their frequency  was noted 
35.4%(Table1). Among surface epithelial tumours , 
serous papillary carcinoma remained the commonest 
in 2001 and 2012(Table 2). Among germ cell    tumours  
Table I: ovarian tumours in 2001 and 2012 
Tumour type 2001 2012 
Surface epithelial tumours 48 (74.2%) 23 (35.4%) 
Germ cell tumours 12 (18.3%) 12 (18.4%) 
Sex cord stromal tumours 1 (1.5%) 4 (6.2%) 
Metastatic ( Total ) 
 
2 (3%) 23 (35.4%) 
Miscellaneous 2 (3%) 3 (4.6%) 
Table 2: Histological types of surface 
epithelial tumours in 2001 and 2012 
Surface Epithelial Tumors 2001 2012 
Serous carcinomas 33(51.1 %) 42 (65.3%) 
Mucinous carcinomas 12 (18.4%) 3 (4.3%) 
Endometrioid carcinomas 11(16.3 %) 14 (21.7%) 
Clear cell carcinomas 9 (14.2 %) 6 (8.7%) 
     Table 3: Immunopanel used for diagnosis of 
primary and secondary ovarian malignancies in 
2001 and 2012 
 Surface 
epithelial 
tumors 
Germ 
cell 
tumors 
Sex cord 
stromal 
tumors 
Metastatic 
tumors 
Immunopanel 
available in 
2001 
CK, CK7 PLAP Inhibin CK, CK7, LCA 
Immunopanel 
available in 
2012 
Ck7, 
CK20, 
WT1, 
cdx2, 
CEA, 
CA125 
PLAP, 
AFP, 
CK7, 
CD117, 
CD30 
Inhibin, 
Calretenin, 
Melan A, 
CD99 
CK7, CK20, 
cdx2, 
GCDFP15, 
Mammoglobin, 
CD10, CEA, 
CA125 
 
  dysgerminoma comprised 61.5% of the cases, 
followed by yolk sac tumours and mixed germ cell 
tumours (15.4% each). In 2012 most common germ cell 
tumour was dysgerminoma (58.4%), followed by 
immature teratoma (16.7%), mixed germ cell tumors 
(16.6%) and yolk sac tumor (8.3%). There was only one 
(1.5%) adult granulosa cell tumour diagnosed in sex 
cord stromal tumour category in 2001 and four adult 
granulosa cell tumors (6.2%) in sex cord stromal 
category in 2012. 
     In 2001, there were only two cases (3%) of 
metastatic carcinoma, one metastasis from 
gastrointestinal tract and other from breast. In 2012, 
there were 23 cases (35.4%) of metastatic carcinoma. 
Among the latter, 2 cases had metastasis from uterus, 
12 from GIT (fig 3, 4, 5), 2 from breast (fig 1and 2) and 
1 from kidney. Six cases had ovarian metastasis of 
unknown origin. Origin could not be determined even 
after application of an extensive panel of antibodies. 
Immunopanel used in 2001 was fairly smaller than 
what we use in 2012 (Table 3). 
 
Discussion 
     Ovarian malignancies rank among the ten most 
common malignancies in Pakistani women. 12 We have 
compared frequencies of ovarian malignancies 
diagnosed during the year 2001 when a very limited 
panel of immunostains was available and 2012 when 
extensive panel of immunostains was available.  
Special emphasis was given in to the role of 
immunohistochemistry in identifying primary and 
secondary malignancies. Presumably, the frequency of 
metastatic carcinoma in ovary has changed after the 
use of IHC. In 2001 the most common tumours were 
surface epithelial tumours (74.2%). Results were 
similar to some Pakistani studies.9-11 In all the later 
Pakistani studies, IHC  was not used. The percentage 
of surface epithelial malignancies dropped from 74.2% 
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Fig 1: Metastatic carcinoma    of breast origin; 
Fig 2: Metastatic carcinoma of breast origin showing 
GCDFP-15 expression (200x) 
 
 
Fig 3: Metastatic colorectal adenocarcinoma(400x); 
Fig 4: Metastatic colorectal  adenocarcinoma showing 
cdx2 expression (100x) 
 
Fig 5: Metastatic colorectal adenocarcinoma showing 
CK20 expression (100x) 
to 35.4% in 2012. This change has resulted from the 
increase in percentage of metastatic carcinomas after 
the use of IHC technique. In present study commonest 
epithelial malignancy was serous carcinoma in both 
years (2001 and 2012). In 2001, serous carcinoma was 
followed by mucinous, endometrioid and clear cell 
carcimomas in decreasing order of frequency, whereas 
in 2012 serous carcinoma was followed by 
endometrioid adenocarcinomas, clear cell carcinomas 
and mucinous carcinomas. The results of 2001 were 
comparable with the studies by Ahmed et al, Tanwani 
et al, showing serous carcinomas commonest, followed 
by mucinous and endometrioid carcinomas.10,11 On the 
other hand in studies by Jamal et al and Khan et al 
serous carcinomas were most common followed by 
endometrioid and mucinous carcinomas. 9,12 In studies 
by Muzaffar et al and Iltaf et al mucinous carcinomas 
were more common than serous carcinomas.13,14  On 
the whole the important point was that, mucinous 
carcinoma occupied the second place in 2001 in our 
study and second or first place in local studies which 
we compared.  In 2012, mucinous tumours dropped to 
fourth place. It can be ascribed to an increase in 
detection rates of metastatic adenocarcinomas after 
using extensive panel of IHC. The role of IHC in 
differentiating primary mucinous carcinoma and 
mucinous carcinomas from gastrointestinal tract is 
limited; nevertheless the combination of light 
microscopic findings, IHC and radiological and 
clinical parameters help in differentiating between the 
two in most of the cases.  Germ cell tumours were the 
second most common group in our study in 2001. 
Results were similar to local studies. 9,10,14  Germ cell 
tumour was second most common tumour (15-20%) in 
few western studies by Greene and Wooster et al.17,15,16 
  An important finding in our study was that the 
metastatic carcinomas shared the similar percentage 
(35.4%) as that by surface epithelial tumours in 2012. 
Metastatic group constituted only a small percentage 
in other studies like Khan et al  (1%) and Iltaf et al 
(0.7%).9,14  In various local studies done on frequencies 
of ovarian malignancies like studies by Saeed et al, 
Muzaffar et al, Jamal et al and Ahmed et al, metastatic 
carcinoma groups constituted a very small 
percentage.12,17,18 International studies, conducted by 
Yada-Hashimoto, Kir and Khunamornpong et al, using 
IHC panels,  revealed the  frequency of metastatic 
tumours from 17.4% to 30%. These higher percentages 
are similar to present study. 19-21  All these studies had 
gastrointestinal tumours as the most common source 
of ovarian metastasis, substantiating the present study. 
In another study by de Waal et al, metastatic ovarian 
carcinomas constituted 15% of ovarian malignancies. 
This number was lower as compared to that of our 
study.22 In another study by Moore RG et al colon 
cancer was the most common source of ovarian 
metastasis (32.2%), followed by appendix (20.3%), 
breast (8.4%) and others.23 Most primary source of 
ovarian metastasis in our study was also GIT.23  
Results were different in study by Skírnisdóttir I et al 
in which the most common source of ovarian 
metastasis was breast carcinoma followed by GIT.24  
Our study had opposite results. Main reason for 
different results may be geographical variations, 
selection of cases and different expertise of different 
tertiary care hospitals. 
     There is a tendency of metastatic carcinomas being 
misdiagnosed as one of the primary surface epithelial 
tumor, if IHC techniques are not used or a limited 
panel is used. The later phenomenon applies mostly to 
mucinous tumors which turn out to be metastasis from 
appendix, intestine or pancreas etc.6 When tumor 
comprises predominantly of signet ring cells, it is 
required, by applying IHC, to rule out metastasis from 
breast and gastrointestinal tract before labeling it as 
primary ovarian carcinoma. Generally panel used in 
our setup to differentiate between primary ovarian 
carcinomas from metastatic carcinoma is: CK7, CK20, 
WT1, ER, PR, GCDFP-15, Mammoglobin, CEA, Cdx2 
and CA 125.  CK7 and CA125 are positive in primary 
3 4 
1 2 
5 
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ovarian surface epithelial tumours with WT1 usually 
positive in serous carcinomas. Clinical and radiological 
correlation are also very much needed. CEA is usually 
positive in metastatic gastrointestinal tumors.  About 
40 % of primary ovarian tumors show expression for 
ER and PR. So ER and PR alone cannot differentiate 
between primary ovarian tumours from metastatic 
breast carcinomas. In this situation, GCDFP-15 and 
mammoglobin play an important role to rule out 
metastasis from breast. Panel which is used to 
differentiate primary endometrioid adenocarcinoma 
from metastatic colonic carcinoma is: CK7, CK20, ER, 
PR, CA125 and Cdx2. Primary endometrioid ovarian 
carcinomas are positive for CA125, CK7, ER, PR but 
usually negative for CK 20 and Cdx2. Reverse is true 
for metastatic colonic adenocarcinomas. A panel of 
CK7, CA125, CK20, Cdx2, ER and PR is used to 
differentiate between primary mucinous and 
metastatic colon carcinoma. Metastatic large intestinal 
adenocarcinomas are positive for CK20 and cdx2 and 
negative for CK7 and CA125. Primary mucinous 
carcinomas of ovary are positive for CA125 and more 
diffusely positive for CK7 than CK20. They can also be 
positive for CDX2. Metastatic carcinomas from upper 
GIT and pancreaticobillary origin are usually positive 
for CK7 and CDx2 and negative for CK7 and CA125. 
However these results are not absolute. There is lot of 
overlapping. Both primary mucinous carcinomas from 
ovary and metastatic carcinomas from GIT can be 
positive with CK20 and CDX2 and negative with CK7 
and CA125.Overlapping IHC results some times 
makes it difficult  to differentiate between primary 
mucinous carcinomas of ovary and metastasis for GIT. 
Then, the combination of clinical history, light 
microscopic, immunohistochemical and radiological 
parameters play an important role. 
Conclusion 
IHC leads towards making an accurate  diagnosis, 
thereby translating into better management options. 
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